SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! #RNL2023 https://t.co/xlw4nzrwpm https://t.co/dhhLMFQnhI